Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
W Schuyler JonesHillary MulderLisa M WruckMichael J PencinaSunil KripalaniDaniel MuñozDavid L CrenshawMark B EffronRichard N ReKamal GuptaR David AndersonCarl J PepineEileen M HandbergBrittney R ManningSandeep K JainSaket GirotraDanielle RileyDarren A DeWaltJeff WhittleYthan H GoldbergVeronique L RogerRachel HessCatherine P BenzigerPeter FarrehiLi ZhouDaniel E FordKevin HaynesJeffrey J VanWormerKirk U KnowltonJennifer L KraschnewskiTamar S PolonskyDan J FintelFaraz S AhmadJames C McClayJames R CampbellDouglas S BellGregg C FonarowSteven M BradleyAnuradha ParanjapeMatthew T RoeHolly R RobertsonLesley H CurtisAmber G SharlowLisa G BerdanBradley G HammillDebra F HarrisLaura G QuallsGuillaume Marquis-GravelMadelaine F ModrowGregory M MarcusThomas W CartonElizabeth NaumanLemuel R WaitmanAbel N KhoElizabeth A ShenkmanKathleen M McTigueRainu KaushalFrederick A MasoudiElliott Marshall AntmanDesiree R DavidsonKevin EdgleyJames G MerrittLinda S BrownDoris N ZemonThomas E McCormickJacqueline D AlikhaaniKenneth C GregoireRussell L RothmanRobert A HarringtonAdrian F Hernandeznull nullPublished in: The New England journal of medicine (2021)
In this pragmatic trial involving patients with established cardiovascular disease, there was substantial dose switching to 81 mg of daily aspirin and no significant differences in cardiovascular events or major bleeding between patients assigned to 81 mg and those assigned to 325 mg of aspirin daily. (Funded by the Patient-Centered Outcomes Research Institute; ADAPTABLE ClinicalTrials.gov number, NCT02697916.).
Keyphrases
- cardiovascular events
- cardiovascular disease
- coronary artery disease
- low dose
- end stage renal disease
- type diabetes
- ejection fraction
- study protocol
- chronic kidney disease
- physical activity
- cardiovascular risk factors
- newly diagnosed
- clinical trial
- prognostic factors
- randomized controlled trial
- atrial fibrillation
- weight loss